bioAffinity Technologies Inc. has announced the release of three new case studies demonstrating the clinical utility of its CyPath® Lung diagnostic test. The cases include detection of Stage 1A lung cancer following a positive CyPath® Lung result, as well as instances where the test helped avoid unnecessary invasive procedures in patients with indeterminate pulmonary nodules. According to the company, these case studies were provided by a Texas pulmonologist who has been using CyPath® Lung for over a year. The results from these cases have already been released by bioAffinity Technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250926999689) on September 26, 2025, and is solely responsible for the information contained therein.